Doctors able to prescribe Australia’s second oral GLP-1 drug ‘within days’

Eli Lilly's orforglipron is the second weight loss pill to be approved in recent weeks.

The TGA has greenlighted a second oral GLP-1 drug to treat type 2 diabetes and chronic weight management, which is expected to be available on private prescription within days. 

Eli Lilly’s orforglipron (Foundayo) was registered by the regulator on Monday, weeks after the approval of Novo Nordisk’s Wegovy pill. 

The manufacturer recommends retail prices of $250 for a 30-day supply of the 0.8mg, 2.5mg and 5.5mg doses, $310 for 9mg, and $370 for 14.5mg and 17.2mg. 

Orforglipron is indicated as an adjunct to a healthy diet and physical activity for weight management and maintenance in patients with an initial BMI of ≥30kg/m² (obesity) or ≥27 to <30kg/m² (overweight) and with at least one weight-related comorbidity.